Sarah R. Beattie

Sarah R. Beattie

Auto-generated profile, based on publicly available information

Sarah R. Beattie

Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SBSarah R Beattie
Sarah R Beattie
KMKenneth M K Mark
Kenneth M K Mark
ATArsa Thammahong
Arsa Thammahong
LRLaure Ries
Laure Ries
SDSourabh Dhingra
Sourabh Dhingra
RCRobert A Cramer
Robert A Cramer
Aspergillus fumigatus is responsible for a disproportionate number of invasive mycosis cases relative to other common filamentous fungi. While many fungal factors critical for infection establishment are known, genes essential for disease persistence and progression are ill defined. We propose that fungal factors that promote navigation of the rapidly changing nutrient and structural landscape characteristic of disease progression represent untapped clinically relevant therapeutic targets. To this end, we find that A. fumigatus requires a carbon catabolite repression (CCR) mediated genetic network to support in vivo fungal fitness and disease progression. While CCR as mediated by the transcriptional repressor CreA is not required for pulmonary infection establishment, loss of CCR inhibits fungal metabolic plasticity and the ability to thrive in the dynamic infection microenvironment. Our results suggest a model whereby CCR in an environmental filamentous fungus is dispensable for initiation of pulmonary infection but essential for infection maintenance and disease progression. Conceptually, we argue these data provide a foundation for additional studies on fungal factors required to support fungal fitness and disease progression and term such genes and factors, DPFs (disease progression factors). Medical treatment advances such as organ transplants and chemotherapies that suppress the immune system have increased the number of patients susceptible to invasive fungal diseases. The most common filamentous fungus isolated from these infections is the environmental mold, Aspergillus fumigatus, the causative agent of invasive aspergillosis (IA). Despite medical intervention, mortality from IA remains high, underscoring the need to understand A. fumigatus pathogenesis mechanisms to uncover new therapeutic targets and strategies. Here, we show that regulation of central metabolism in A. fumigatus is critical for infection maintenance and progression of disease. The dysregulation of carbon catabolite repression results in reduced virulence in an animal model at later stages of the infection because of an inability to navigate infection microenvironment dynamics driven in part by oxygen depletion and alterations in nutrient availability. These results likely not only apply to IA, but are broadly applicable to other infection models stressing the need to understand spatiotemporal dynamics of individual microbial infections particularly at the level of metabolism. We propose that microbial genes which support disease progression, in contrast but not mutually exclusive to disease initiation, be termed DPFs (disease progression factors) and as such represent a novel class of antimicrobial drug targets.

8 September 2017 in Science
Verified
Journal Article
Closed access
PDF file
NSNeta Shlezinger
Neta Shlezinger
HIHenriette Irmer
Henriette Irmer
SDSourabh Dhingra
Sourabh Dhingra
SBSarah R. Beattie
Sarah R. Beattie
RCRobert A. Cramer
Robert A. Cramer
THTobias M. Hohl
Tobias M. Hohl
Survivin' neutrophil surveillance: Humans constantly inhale fungal spores. Why don't we suffer more invasive infections from ubiquitous fungal molds such as Aspergillus fumigatus ? Working in mice, Shlezinger et al. found that neutrophils phagocytosed germinating fungal spores deep in the lungs (see the Perspective by Wiesner and Klein). Once engulfed, the fungal cells underwent programmed cell death, likely induced by phagocyte NADPH oxidase. Fungal strains engineered to overexpress a fungal survivin homolog resisted cell death by inhibiting caspase-3 and -7. When a Survivin antagonist was applied, more fungal cells died. These findings may lead to therapies for immunocompromised patients threatened by invasive fungal lung infections. Science , this issue p. 1037 ; see also p. 973

26 April 2022 in mBio
Verified
Journal Article
Open access
JKJoshua D. Kerkaert
Joshua D. Kerkaert
FMFrançois Le Mauff
François Le Mauff
BWBenjamin R. Wucher
Benjamin R. Wucher
SBSarah R. Beattie
Sarah R. Beattie
EVElisa M. Vesely
Elisa M. Vesely
RCRobert A. Cramer
Robert A. Cramer
Aspergillus fumigatus is a ubiquitous filamentous fungus that causes an array of diseases depending on the immune status of an individual, collectively termed aspergillosis. Antifungal therapy for invasive pulmonary aspergillosis (IPA) or chronic pulmonary aspergillosis (CPA) is limited and too often ineffective.

25 August 2021 in mSphere
Verified
Journal Article
Open access
SBSarah R Beattie
Sarah R Beattie
DKDamian J Krysan
Damian J Krysan
Fungal infections caused by molds have the highest mortality rates of human fungal infections. These devastating infections are hard to treat and available antifungal drugs are often not effective.

19 December 2024 in mSphere
Verified
Journal Article
Open access
TCThomas P. Conway
Thomas P. Conway
BVBao Gia Vu
Bao Gia Vu
SBSarah R. Beattie
Sarah R. Beattie
DKDamian J. Krysan
Damian J. Krysan
WMW. Scott Moye-Rowley
W. Scott Moye-Rowley
Incidences of fluconazole (FLC) resistance among Candida glabrata clinical isolates are a growing issue in clinics. The pleiotropic drug response network in C. glabrata confers azole resistance and is defined primarily by the Zn 2 Cys 6 zinc cluster-containing transcription factor Pdr1 and target genes such as CDR1 , which encodes an ATP-binding cassette transporter protein thought to act as an FLC efflux pump. Mutations in the PDR1 gene that render the transcription factor hyperactive are the most common cause of fluconazole resistance among clinical isolates. The phenothiazine class drug fluphenazine and a molecular derivative, CWHM-974, which both exhibit antifungal properties, have been shown to induce the expression of Cdr1 in Candida spp. We have used a firefly luciferase reporter gene driven by the CDR1 promoter to demonstrate two distinct patterns of CDR1 promoter activation kinetics: gradual promoter activation kinetics that occur in response to ergosterol limitations imposed by exposure to azole and polyene class antifungals and a robust and rapid CDR1 induction occurring in response to the stress imposed by fluphenazines. We can attribute these different patterns of CDR1 induction as proceeding through the promoter region of this gene since this is the only segment of the gene included in the luciferase reporter construct. Genetic analysis indicates that the signaling pathways responsible for phenothiazine and azole induction of CDR1 overlap but are not identical. The short time course of phenothiazine induction suggests that these compounds may act more directly on the Pdr1 protein to stimulate its activity. IMPORTANCE: Candida glabrata has emerged as the second-leading cause of candidiasis due, in part, to its ability to acquire high-level resistance to azole drugs, a major class of antifungal that acts to block the biosynthesis of the fungal sterol ergosterol. The presence of azole drugs causes the induction of a variety of genes involved in controlling susceptibility to this drug class, including drug transporters and ergosterol biosynthetic genes such as ERG11. We found that the presence of azole drugs leads to an induction of genes encoding drug transporters and ERG11, while exposure of C. glabrata cells to antifungals of the phenothiazine class of drugs caused a much faster and larger induction of drug transporters but not ERG11. Coupled with further genetic analyses of the effects of azole and phenothiazine drugs, our data indicate that these compounds are sensed and responded to differentially in the yeast cell.

6 August 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
MKMartin T. Kelty
Martin T. Kelty
AMAracely Miron-Ocampo
Aracely Miron-Ocampo
SBSarah R. Beattie
Sarah R. Beattie
Fungal infections are a major contributor to morbidity and mortality among immunocompromised populations. Moreover, fungal disease caused by molds are difficult to treat and are associated with particularly high mortality. To address the need for new mold-active antifungal drugs, we performed a high-throughput screen with Aspergillus fumigatus , the most common pathogenic mold. We identified a novel, pyrimidine-based chemical scaffold with broad-spectrum antifungal activity including activity against several difficult-to-treat molds. A chemical genetics screen of Saccharomyces cerevisiae suggested that this compound may target the endoplasmic reticulum (ER) and perturb ER function and/or homeostasis. Consistent with this model, this compound induces the unfolded protein response and inhibits secretion of A. fumigatus collagenases. Initial cytotoxicity and pharmacokinetic studies show favorable features including limited mammalian cell toxicity and bioavailability in vivo . Together, these data support the further medicinal chemistry and pre-clinical development of this pyrimidine scaffold toward more effective treatments for life-threatening invasive mold infections. IMPORTANCE: Invasive fungal diseases are life-threatening infections caused by fungi in immunocompromised individuals. Currently, there are only three major classes of antifungal drugs available to treat fungal infections; however, these options are becoming even more limited with the global emergence of antifungal drug resistance. To address the need for new antifungal therapies, we performed a screen of chemical compounds and identified a novel molecule with antifungal activity. Initial characterization of this compound shows drug-like features and broad-spectrum activity against medically important fungi. Together, our results support the continued development of this compound as a potential future therapy for these devastating fungal infections.